Treating Depression to Improve Survival in Coronary Heart Disease: What Have We Learned?

J Am Coll Cardiol. 2024 Jul 30;84(5):482-489. doi: 10.1016/j.jacc.2024.05.038.

Abstract

Major depressive disorder is a well-established risk factor for cardiac events in patients with coronary heart disease, but clinical trials have produced little evidence that treating depression reliably improves cardiac event-free survival in these patients. In this review, we offer evidence that certain symptoms that commonly remain after otherwise successful treatment of depression-insomnia, fatigue, and anhedonia-independently predict cardiac events. This may help to explain the failure of previous depression treatment trials to improve cardiac event-free survival even when other symptoms of depression improve. We thus propose that adverse cardiovascular effects that have long been attributed to syndromal depression may be instead caused by persistent fatigue, insomnia, and anhedonia, regardless of whether other symptoms of depression are present. We also identify interventions for these symptoms and call for more research to evaluate their effectiveness in depressed patients with coronary heart disease.

Keywords: anhedonia; antidepressive agents; depressive disorder major; fatigue; myocardial ischemia; sleep wake disorders.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Coronary Disease* / complications
  • Coronary Disease* / mortality
  • Coronary Disease* / psychology
  • Depression / therapy
  • Depressive Disorder, Major / psychology
  • Depressive Disorder, Major / therapy
  • Humans

Substances

  • Antidepressive Agents